Daniel C Chung

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1545823/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study. Clinical and Translational Gastroenterology, 2022, 13, e00468.	1.3	17
2	The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer Journal of Clinical Oncology, 2022, 40, e16239-e16239.	0.8	0
3	Surveillance Endoscopy in the Management of Hereditary Diffuse Gastric Cancer Syndrome. Clinical Gastroenterology and Hepatology, 2021, 19, 189-191.	2.4	15
4	A pilot study of virtual reality as an alternative to pharmacological sedation during colonoscopy. Endoscopy International Open, 2021, 09, E343-E347.	0.9	3
5	NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1122-1132.	2.3	68
6	Microscopic Colitis Is Characterized by Intestinal Dysbiosis. Clinical Gastroenterology and Hepatology, 2020, 18, 984-986.	2.4	34
7	Health Care Provider Perceptions of Caring for Individuals with Inherited Pancreatic Cancer Risk. Journal of Cancer Education, 2020, 35, 194-203.	0.6	3
8	Fruit and vegetable consumption is associated with lower prevalence of asymptomatic diverticulosis: a cross-sectional colonoscopy-based study. BMC Gastroenterology, 2020, 20, 221.	0.8	4
9	Reply. Clinical Gastroenterology and Hepatology, 2020, 18, 1648.	2.4	2
10	Gastric cancer in Lynch syndrome is associated with underlying immune gastritis. Journal of Medical Genetics, 2019, 56, 844-845.	1.5	19
11	Cancer risk in microscopic colitis: a retrospective cohort study. BMC Gastroenterology, 2019, 19, 1.	0.8	48
12	Costâ€effectiveness of immune checkpoint inhibitors for microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer. Cancer, 2019, 125, 278-289.	2.0	24
13	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1032-1041.	2.3	191
14	Genetic Testing and Early Onset Colon Cancer. Gastroenterology, 2018, 154, 788-789.	0.6	13
15	Obesity, but Not Physical Activity, Is Associated With Higher Prevalence of Asymptomatic Diverticulosis. Clinical Gastroenterology and Hepatology, 2018, 16, 586-587.	2.4	10
16	Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome. Cancer, 2018, 124, 3145-3153.	2.0	72
17	Nivolumab versus nivolumab with ipilimumab versus trifluridine/tipiracil for metastatic microsatellite instability-high colorectal cancer: A modeling decision analysis Journal of Clinical Oncology, 2018, 36, 829-829.	0.8	0
18	Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer Journal of Clinical Oncology, 2018, 36, e15134-e15134.	0.8	0

DANIEL C CHUNG

#	Article	IF	CITATIONS
19	A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome. Modern Pathology, 2017, 30, 440-447.	2.9	62
20	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1465-1475.	2.3	109
21	Working up rectal bleeding in adult primary care practices. Journal of Evaluation in Clinical Practice, 2017, 23, 279-287.	0.9	8
22	Survival outcomes and surgical intervention of small intestinal neuroendocrine tumors: a population based retrospective study. Oncotarget, 2017, 8, 4935-4947.	0.8	25
23	c-Myc is regulated by HIF-2α in chronic hypoxia and influences sensitivity to 5-FU in colon cancer. Oncotarget, 2016, 7, 78910-78917.	0.8	25
24	Pilot Clinical Trial of Indocyanine Green Fluorescence-Augmented Colonoscopy in High Risk Patients. Gastroenterology Research and Practice, 2016, 2016, 1-7.	0.7	4
25	Clinical Genetic Testing in Gastroenterology. Clinical and Translational Gastroenterology, 2016, 7, e167.	1.3	0
26	Case 6-2016. New England Journal of Medicine, 2016, 374, 772-781.	13.9	5
27	Screening for Pancreatic Adenocarcinoma in BRCA2 Mutation Carriers: Results of a Disease Simulation Model. EBioMedicine, 2015, 2, 1980-1986.	2.7	14
28	Interval Colorectal Cancer After Colonoscopy. Clinical Colorectal Cancer, 2015, 14, 46-51.	1.0	30
29	The Enigma of Carcinoids. Gastroenterology, 2015, 149, 14-15.	0.6	2
30	Metakaryotic stem cell nuclei use pangenomic dsRNA/DNA intermediates in genome replication and segregation. Organogenesis, 2014, 10, 44-52.	0.4	9
31	Germline Mutations in Oncogene-Induced Senescence Pathways Are Associated With Multiple Sessile Serrated Adenomas. Gastroenterology, 2014, 146, 520-529.e6.	0.6	121
32	Mismatch repair protein loss and microsatellite instability in cholangiocarcinoma Journal of Clinical Oncology, 2014, 32, 237-237.	0.8	6
33	Oncogenic KRAS regulates BMP4 expression in colon cancer cell lines. American Journal of Physiology - Renal Physiology, 2012, 302, G1223-G1230.	1.6	7
34	Reply to S. Sciallero et al. Journal of Clinical Oncology, 2010, 28, e538-e538.	0.8	0
35	Case 22-2007. New England Journal of Medicine, 2007, 357, 283-291.	13.9	57
36	Hypoxia, angiogenesis, and colorectal cancer. Current Colorectal Cancer Reports, 2007, 3, 71-75.	1.0	3

DANIEL C CHUNG

#	Article	IF	CITATIONS
37	New insights into the molecular pathogenesis of colorectal cancer. Drug Discovery Today Disease Mechanisms, 2006, 3, 439-445.	0.8	8
38	Hypoxic Regulation of Vascular Endothelial Growth Factor through the Induction of Phosphatidylinositol 3-Kinase/Rho/ROCK and c-Myc*. Journal of Biological Chemistry, 2006, 281, 13957-13963.	1.6	85
39	Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis. Cancer Biology and Therapy, 2005, 4, 1361-1366.	1.5	17
40	Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells. Nature Medicine, 2005, 11, 992-997.	15.2	394
41	Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer Patients. Journal of Clinical Oncology, 2005, 23, 8136-8139.	0.8	410
42	Oncogenic K-ras Stimulates Wnt Signaling in Colon Cancer Through Inhibition of GSK-3β. Gastroenterology, 2005, 128, 1907-1918.	0.6	92
43	Hypoxia-Inducible Factor-1-Independent Regulation of Vascular Endothelial Growth Factor by Hypoxia in Colon Cancer. Cancer Research, 2004, 64, 1765-1772.	0.4	148
44	Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Medicine, 2004, 10, 145-147.	15.2	1,852
45	Cyclin D1 in Human Neuroendocrine: Tumorigenesis. Annals of the New York Academy of Sciences, 2004, 1014, 209-217.	1.8	25
46	Case 34-2003. New England Journal of Medicine, 2003, 349, 1750-1760.	13.9	13
47	Overexpression of Cyclin D1 Occurs Frequently in Human Pancreatic Endocrine Tumors1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4373-4378.	1.8	67
48	The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis. Gastroenterology, 2000, 119, 854-865.	0.6	372
49	Mutational analysis of the CDK-4 gene in human pancreatic endocrine tumors. Gastroenterology, 2000, 118, A1157.	0.6	1
50	Analysis of the retinoblastoma tumour suppressor gene in pancreatic endocrine tumours. Clinical Endocrinology, 1997, 47, 523-528.	1.2	44